

Prevas Bioinformatics Wins Contract from Maxygen

Prevas Bioinformatics A/S will supply senior level bioinformatics expertise to conduct a feasibility study for Maxygen. The aim of the study is to analyze manual routines and databases currently used in the characterization of protein leads, to identify bottlenecks in genetic analyses and to suggest implementation of customized software and laboratory information systems to streamline the discovery process.

Maxygen focuses on creating innovative products using its integrated proprietary technologies for human therapeutics and industrial applications. Maxygen's technologies bring together advances in molecular biology and protein modification to create new biotechnology products.

"This is a very important step for us. The contract with Maxygen is yet another milestone in the launch of Prevas Bioinformatics in Denmark.", says Hans Fondelius, Vice President of Prevas Bioinformatics.

Contacts

Hans Fondelius, Vice President, Prevas Bioinformatics

Phone: +46 (0)8 726 40 63

E-mail: hans.fondelius@prevas.se

Michael Lehd, Managing director, Prevas Bioinformatics A/S

Phone: +45 51 35 77 34

E-mail: michael.lehd@prevas.dk

About Prevas

Prevas is a successful IT consultancy that currently employs around 240 people in the fields of bioinformatics, industry and telecom. Prevas is listed on the O-list of the Stockholm Stock Exchange. Prevas' IT solutions are distinguished by a high standard of quality and reliable delivery at a fixed price.

See also www.prevas.com